|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
One way of streamlining tech transfer is to partner with a CMO demonstrating a proven track record across the entire drug development and manufacturing continuum. Not only will an experienced CMO partner have the scientific….
|
|
 |
|
Neil Vivian believes advances in electronic data collection and analysis are helping to make DCTs more accessible to broader and more diverse patient populations. Further innovations, particularly in artificial intelligence technology, are expected to accelerate these trends.
|
|
|
|
|
|
|
|
|
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
|
|
|
Jim Huang, PhD, and Shaukat Ali, PhD, say as we continue our investigation of innovative delivery routes for drug molecules besides the parenteral and oral routes, the IN route remains the future method for drug delivery to the brain.
|
|
|
Shota Arakawa, MSc, and Tomohiro Suzuki believe OXYCAPT offers a multitude of benefits to the rapidly growing field of cell and gene therapy products.
|
|
|
David-Alexandre C. Gros, MD, explains how researchers are targeting strategies in immunosuppression that can help donated kidneys remain healthy and viable for much longer post-transplant, thus alleviating the need for repeat transplants and making more organs available for first-time transplant recipients.
|
|
|
Vanessa Zann, PhD, presents the opportunities and challenges when transitioning from an IR to MR formulation, and reviews the therapeutic benefits and challenges associated with MR formulations, GI physiology environments and API physicochemical properties, technology choices, and how drug developers can achieve translation success.
|
|
|
Andreas Eschbach says a people-centered approach to digitizing manufacturing operations helps ensure the success of any digitalization initiative. But in pharmaceutical manufacturing, having insights into each area of operation is critical to production quality and compliance.
|
|
|
Gael Touya, President of Aptar Pharma, and Sai Shankar, President, M&A, Strategy, BD, Marketing, Drug Services, Aptar Pharma, discuss the burgeoning potential in the future of pharma and digital health, how the company is a strategic partner to key players in these spaces, and the investments Aptar is making to support the growing demand.
|
|
|
|
|
|
|
|
|

Woodstock Sterile Solutions is a global provider of best-in-class sterile development and manufacturing solutions – with a decades-long track record of helping healthcare companies advance molecules through clinical development into full-scale commercial production. Throughout our 50-year history, Woodstock has been a leader in developing and deploying advanced aseptic blow-fill-seal delivery products. Today, Woodstock Sterile Solutions is a reliable partner in the development of complex, high-quality sterile products from ophthalmic and respiratory therapeutics to diagnostics and complex orals. Our experience with formulation and the development cycle is a core strength. Woodstock Sterile Solutions is at its best with complex solutions, suspensions, and emulsions, as well as biologics, sterile products, potent compounds, and sensitive APIs. Click here for more.
|
|
|
|
|
|
 |
|
Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….
|
|
|
|
|
|
|
|
 |
|
A clear standard for identifying APIs susceptible to Nitrosamine Drug Substance-Related Impurities (NDSRI) formation has been elusive—until now. Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs. Discover how this innovative approach …
|
|
 |
|
Mucoadhesion Matters
And so does your choice of mucoadhesive polymer.
This technical brief will cover the use of polymers in a variety of dosage forms (buccal/sublingual tablets, liquid, semi-solid formulations, and oral care products) to impart mucoadhesion. The basic mechanism …
|
|
 |
|
It is widely reported that 40% of New Chemical Entities (NCEs) in the pharmaceutical industry are poorly soluble, leading to inadequate bioavailablity. Spray drying is one of the most promising particle engineering technologies used to overcome solubility issues in active …
|
|
 |
|
When a mid-sized pharmaceutical company asked Adare to make a version of their drug that was more convenient for patients with tremors or swallowing difficulties, our experts created a sprinkle formulation of the drug. In this CPHI Award-winning case study, …
|
|
|
|
|
Upcoming eNewsletter Features:
January 8 – Capsules
January 15 – Excipients
|
|
|
|
|
|
|
|